Startups
2011
IPROTEOS SLiProteos is a R&D; pharma company, a spin-off from the Institute for Research in Biomedicine (IRB, Barcelona, Spain) and the Universitat de Barcelona (UB, Spain), developing new medicines to treat brain disorders with a high social and economic impact worldwide. The company has benefited from a Series A financing led by Caixa Capital Risk and Kinled.
iProteos demonstrated the effectiveness of 2 compounds in animal models:
IPR-166 (propyl oligopeptidase inhibitor) to reverse the cognitive deficit associated with certain brain disorders
IPR-179 (gelatinase inhibitor) to act directly on epileptogenesis, thus preventing the appearance of seizures in patients suffering from epilepsy
Since May 26, 2020, the two programs, IPT-166 and IPR-179, have been integrated into the portfolio of Accure Therapeutic (accure.health) under the names ACT-02 and ACT-03 respectively.
iProteos demonstrated the effectiveness of 2 compounds in animal models:
IPR-166 (propyl oligopeptidase inhibitor) to reverse the cognitive deficit associated with certain brain disorders
IPR-179 (gelatinase inhibitor) to act directly on epileptogenesis, thus preventing the appearance of seizures in patients suffering from epilepsy
Since May 26, 2020, the two programs, IPT-166 and IPR-179, have been integrated into the portfolio of Accure Therapeutic (accure.health) under the names ACT-02 and ACT-03 respectively.
Address
Passeig de Joan de Borbó 99, 08039 Barcelona, Spain
Finance Data
CERCA ownership
Barcelona, Spain
2005
Institut de Recerca Biomèdica (IRB Barcelona)
CERCA Center Contact
CH
Cristina Horcajada
Institut de Recerca Biomèdica (IRB Barcelona)Other Catalan Public owners
Logo
Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Product description
Effectiveness of 2 compounds in animal models:
IPR-166 (propyl oligopeptidase inhibitor) to reverse the cognitive deficit associated with certain brain disorders
IPR-179 (gelatinase inhibitor) to act directly on epileptogenesis, thus preventing the appearance of seizures in patients suffering from epilepsy
IPR-166 (propyl oligopeptidase inhibitor) to reverse the cognitive deficit associated with certain brain disorders
IPR-179 (gelatinase inhibitor) to act directly on epileptogenesis, thus preventing the appearance of seizures in patients suffering from epilepsy
Company Closed or Exit Year